# CAM2029 (octreotide subcutaneous depot)

Source: https://onco.cc/drugs/cam2029/  
OnCo record `cam2029` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CAM2029 is Camurus's monthly octreotide depot that patients can inject themselves, positive in the phase 3 SORENTO trial for gastroenteropancreatic neuroendocrine tumours against the standard depot formulations.

## Summary

Camurus of Lund built CAM2029 on its FluidCrystal lipid depot so that octreotide can be given as a small subcutaneous self-injection rather than the intramuscular Sandostatin LAR. The phase 3 SORENTO trial in advanced gastroenteropancreatic neuroendocrine tumours met its primary endpoint of progression-free survival against octreotide LAR or lanreotide, and the company has filed in Europe and the United States; it is approved for acromegaly as Oczyesa in some markets.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Modality: Peptide somatostatin analogue (octreotide) in a long-acting subcutaneous depot
- Mechanism: Octreotide, a somatostatin analogue, released for a month from a lipid depot that forms under the skin after a small ready-to-use injection.

## Sources

- ClinicalTrials.gov: trials of CAM2029 (octreotide subcutaneous depot): https://clinicaltrials.gov/search?intr=CAM2029%20(octreotide%20subcutaneous%20depot)

## Connected records

- cancers: [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/)
- technologies: [Endocrine therapy (SERMs, AIs, SERDs)](https://onco.cc/technologies/endocrine-therapy/)
- targets: [Somatostatin receptor 2](https://onco.cc/targets/sstr2/)
- trials: [A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET](https://onco.cc/trials/nct05050942/)

---
JSON: https://onco.cc/api/v1/entities/cam2029.json